Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Ever Supreme Bio Technology Co's revenue for the
three
months ended in Jun. 2026 was NT$272 Mil.
Its revenue for the trailing twelve months (TTM) ended in Jun. 2026 was NT$1,081 Mil.
Ever Supreme Bio Technology Co's Revenue per Share for the
three
months ended in Jun. 2026 was NT$2.69.
Its Revenue per Share for the trailing twelve months (TTM) ended in Jun. 2026 was NT$11.31.
Warning Sign:
Ever Supreme Bio Technology Co Ltd revenue growth has slowed down over the past 12 months.
During the past 10 years, Ever Supreme Bio Technology Co's highest 3-Year average Revenue per Share Growth Rate was 273.30% per year. The lowest was 18.90% per year. And the median was 71.70% per year.
His favorite companies are stalwart, those growing between 10-20% a year.
Companies in cyclical industries may see their revenue fluctuate wildly in good years and bad years.
Be Aware
Revenue can be manipulated by changing the way how revenue is booked. Companies may book sales before the payment is received, or before the revenue is fully earned. These will be added to balance sheet items such as account payable or account receivables.
Ever Supreme Bio Technology Co Revenue Related Terms
Ever Supreme Bio Technology Co Revenue Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Ever Supreme Bio Technology Co's Revenue, along with its competitors' market caps and Revenue data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Ever Supreme Bio Technology Co Revenue vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Ever Supreme Bio Technology Co's Revenue distribution charts can be found below:
* The bar in red indicates where Ever Supreme Bio Technology Co's Revenue falls into.
Ever Supreme Bio Technology Co Revenue Calculation
Also referred as sales, revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top.
Revenue for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$1,081 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Ever Supreme Bio Technology Co (ROCO:6712) has a Revenue of NT$1,081 Mil as of Jun. 2026. Revenue is the total amount a company generates as sales through its operations. View historical data on Ever Supreme Bio Technology Co and its competitors.
Is Ever Supreme Bio Technology Co's Revenue too high?
Ever Supreme Bio Technology Co's current Revenue is NT$1,081 Mil. Overall, Ever Supreme Bio Technology Co has a GF Score™ of 92/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Ever Supreme Bio Technology Co's Revenue compare to VRTX and REGN?
Ever Supreme Bio Technology Co's Revenue of NT$1,081 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Revenue for a Biotechnology company?
A good Revenue depends on the Biotechnology industry context. However, Revenue should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Revenue mean?
A high Revenue can signal that a stock is expensive relative to its fundamentals. Revenue is the total amount a company generates as sales through its operations. View historical data on Ever Supreme Bio Technology Co and its competitors. Ever Supreme Bio Technology Co's current Revenue is NT$1,081 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ever Supreme Bio Technology Co stock overvalued right now?
Based on GuruFocus' analysis, Ever Supreme Bio Technology Co (ROCO:6712) is currently considered Modestly Undervalued. The stock's GF Value™ is NT$180.18, compared to a current price of NT$156.00 — trading 13.4% below its estimated fair value. The current Revenue is NT$1,081 Mil. Ever Supreme Bio Technology Co's overall GF Score™ is 92/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Revenue calculated?
Revenue is calculated from a company's financial statements. For Ever Supreme Bio Technology Co (ROCO:6712), the current Revenue is NT$1,081 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Ever Supreme Bio Technology Co (ROCO:6712) Overvalued in 2026?
Based on GuruFocus' analysis, Ever Supreme Bio Technology Co stock appears to be undervalued.
The current stock price of NT$156.00 is trading 13.4% below its estimated GF Value™ of NT$180.18.
GuruFocus considers Ever Supreme Bio Technology Co to be Modestly Undervalued.
Key valuation signals for ROCO:6712:
Revenue: NT$1,081 Mil
GF Value™: NT$180.18 vs. price of NT$156.00 (13.4% below fair value)
No single metric tells the full story. See the ROCO:6712 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Ever Supreme Bio Technology Co Ltd is a Taiwan-based company. The company is engaged in research, development, and manufacturing of new drugs related to human mesenchymal stem cells and immune cells. The company operates in two segments: Cell Preparation Business Unit and Other Operating Business. The company gained a majority of revenue from the Cell Preparation Business, which is engaged in the research, development, manufacture, and sales of various new drugs and cell preparations, and investments related to biotechnology and medical industry businesses.
92GF Score
Get the complete analysis for ROCO:6712
Revenue is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:6712 has been successfully added to your 
